Amedeo Smart

Free Medical Literature Service

 

Amedeo

Antiretroviral Therapy
  Free Subscription

Articles published in
Antimicrob Agents Chemother
    April 2024
  1. CHANDASANA H, Singh R, Adkison K, Ait-Khaled M, et al
    Population pharmacokinetic modeling of dolutegravir/lamivudine to support a once-daily fixed-dose combination regimen in virologically suppressed adults living with HIV-1.
    Antimicrob Agents Chemother. 2024 Apr 8:e0150423. doi: 10.1128/aac.01504.
    >> Share

    March 2024
  2. WANG C, Yu X, Ke Y, Fu Y, et al
    Efficacy and effect on lipid profiles of switching to ainuovirine-based regimen versus continuing efavirenz-based regimen in people with HIV-1: 24-week results from a real-world, retrospective, multi-center cohort study.
    Antimicrob Agents Chemother. 2024 Mar 14:e0166823. doi: 10.1128/aac.01668.
    >> Share

    February 2024
  3. MULATO A, Lansdon E, Aoyama R, Voigt J, et al
    Preclinical characterization of a non-peptidomimetic HIV protease inhibitor with improved metabolic stability.
    Antimicrob Agents Chemother. 2024 Feb 21:e0137323. doi: 10.1128/aac.01373.
    >> Share

    January 2024
  4. YANG H, Yu X, Hou W, Liu X, et al
    Effectiveness and safety of nirmatrelvir-ritonavir in kidney transplant recipients with severe kidney dysfunction infected with COVID-19.
    Antimicrob Agents Chemother. 2024 Jan 30:e0138423. doi: 10.1128/aac.01384.
    >> Share

    December 2023
  5. ZHANG H, Zhou J, Chen H, Mao J, et al
    Phase I study, and dosing regimen selection for a pivotal COVID-19 trial of GST-HG171.
    Antimicrob Agents Chemother. 2023 Dec 15:e0111523. doi: 10.1128/aac.01115.
    >> Share

  6. ABDALLA S, Compagnucci A, Riault Y, Chan MK, et al
    Simultaneous pharmacokinetic modeling of unbound and total darunavir with ritonavir in adolescents: a substudy of the SMILE trial.
    Antimicrob Agents Chemother. 2023 Dec 11:e0100423. doi: 10.1128/aac.01004.
    >> Share

    October 2023
  7. KENGO A, Gausi K, Nabisere R, Musaazi J, et al
    Unexpectedly low drug exposures among Ugandan patients with TB and HIV receiving high-dose rifampicin.
    Antimicrob Agents Chemother. 2023 Oct 18:e0043123. doi: 10.1128/aac.00431.
    >> Share

    May 2023
  8. HAO X, Ni J, Zhao D, Zhang W, et al
    No Meaningful Drug-Drug Interactions Are Associated with the Coadministration of ACC007, Lamivudine, and Tenofovir Disoproxil Fumarate.
    Antimicrob Agents Chemother. 2023 May 1:e0121922. doi: 10.1128/aac.01219.
    >> Share

    April 2023
  9. BERTRAND J, Barrail-Tran A, Fayette L, Savic R, et al
    Pharmacokinetic Model of Tenofovir and Emtricitabine and Their Intracellular Metabolites in Patients in the ANRS 134-COPHAR 3 Trial Using Dose Records.
    Antimicrob Agents Chemother. 2023 Apr 26:e0233918. doi: 10.1128/aac.02339.
    >> Share

  10. ELGAMMAL Y, Salama EA, Seleem MN
    Atazanavir Resensitizes Candida auris to Azoles.
    Antimicrob Agents Chemother. 2023 Apr 24:e0163122. doi: 10.1128/aac.01631.
    >> Share

    March 2023
  11. MARZINKE MA, Fogel JM, Wang Z, Piwowar-Manning E, et al
    Extended Analysis of HIV Infection in Cisgender Men and Transgender Women Who Have Sex with Men Receiving Injectable Cabotegravir for HIV Prevention: HPTN 083.
    Antimicrob Agents Chemother. 2023 Mar 30:e0005323. doi: 10.1128/aac.00053.
    >> Share

  12. HONG H, Aslam-Mir U, Kajubi R, Wallender E, et al
    Efavirenz-Based Antiretroviral Therapy but Not Pregnancy Increased Unbound Piperaquine Exposure in Women during Malaria Chemoprevention.
    Antimicrob Agents Chemother. 2023 Mar 14:e0142722. doi: 10.1128/aac.01427.
    >> Share

    February 2023
  13. CHIREHWA MT, Resendiz-Galvan JE, Court R, De Kock M, et al
    Optimizing Moxifloxacin Dose in MDR-TB Participants with or without Efavirenz Coadministration Using Population Pharmacokinetic Modeling.
    Antimicrob Agents Chemother. 2023 Feb 6:e0142622. doi: 10.1128/aac.01426.
    >> Share

    December 2022
  14. BURDETTE D, Hyrina A, Song Z, Beran RK, et al
    Characterization of a Novel Capsid Assembly Modulator for the Treatment of Chronic Hepatitis B Virus Infection.
    Antimicrob Agents Chemother. 2022 Dec 15:e0134822. doi: 10.1128/aac.01348.
    >> Share

    November 2022
  15. BANDA CG, Nkosi D, Allen E, Workman L, et al
    Impact of Dolutegravir-Based Antiretroviral Therapy on Piperaquine Exposure following Dihydroartemisinin-Piperaquine Intermittent Preventive Treatment of Malaria in Pregnant Women Living with HIV.
    Antimicrob Agents Chemother. 2022 Nov 14:e0058422. doi: 10.1128/aac.00584.
    >> Share

    October 2022
  16. LINGSCHEID T, Kinzig M, Kruger A, Muller N, et al
    Pharmacokinetics of Nirmatrelvir and Ritonavir in COVID-19 Patients with End-Stage Renal Disease on Intermittent Hemodialysis.
    Antimicrob Agents Chemother. 2022 Oct 26:e0122922. doi: 10.1128/aac.01229.
    >> Share

    August 2022
  17. PHAM MM, Podany AT, Mwelase N, Supparatpinyo K, et al
    Population Pharmacokinetic Modeling and Simulation of Rifapentine Supports Concomitant Antiretroviral Therapy with Efavirenz and Non-Weight Based Dosing.
    Antimicrob Agents Chemother. 2022 Aug 9:e0238521. doi: 10.1128/aac.02385.
    >> Share

    July 2022
  18. DEVANATHAN AS, White NR, Desyaterik Y, De la Cruz G, et al
    Quantitative Imaging Analysis of the Spatial Relationship between Antiretrovirals, Reverse Transcriptase Simian-Human Immunodeficiency Virus RNA, and Fibrosis in the Spleens of Nonhuman Primates.
    Antimicrob Agents Chemother. 2022 Jul 20:e0060922. doi: 10.1128/aac.00609.
    >> Share

  19. MTSHALI S, Jacobs BA
    A Comparative Analysis of Physiologically Based Pharmacokinetic Models for Human Immunodeficiency Virus and Tuberculosis Infections.
    Antimicrob Agents Chemother. 2022 Jul 19:e0027422. doi: 10.1128/aac.00274.
    >> Share

  20. KIM JH, Kim JH, Choe WH, Kwon SY, et al
    Switching from Tenofovir-Based Combination Therapy to Tenofovir Monotherapy in Multidrug-Experienced Chronic Hepatitis B Patients: a 5-Year Experience at Two Centers.
    Antimicrob Agents Chemother. 2022 Jul 13:e0027522. doi: 10.1128/aac.00275.
    >> Share

  21. ATMAR RL, Finch N
    New Perspectives on Antimicrobial Agents: Molnupiravir and Nirmatrelvir/Ritonavir for Treatment of COVID-19.
    Antimicrob Agents Chemother. 2022 Jul 12:e0240421. doi: 10.1128/aac.02404.
    >> Share

    May 2022
  22. DE NICOLO A, Calcagno A, Motta I, De Vivo E, et al
    The Effect of Rifampicin on Darunavir, Ritonavir, and Dolutegravir Exposure within Peripheral Blood Mononuclear Cells: a Dose Escalation Study.
    Antimicrob Agents Chemother. 2022 May 18:e0013622. doi: 10.1128/aac.00136.
    >> Share

  23. VAN DER LAAN LE, Garcia-Prats AJ, Schaaf HS, Chirehwa M, et al
    Pharmacokinetics and Dose Optimization Strategies of Para-Aminosalicylic Acid in Children with Rifampicin-Resistant Tuberculosis.
    Antimicrob Agents Chemother. 2022 May 4:e0226421. doi: 10.1128/aac.02264.
    >> Share

  24. LAI MT, Feng M, Xu M, Ngo W, et al
    Doravirine and Islatravir Have Complementary Resistance Profiles and Create a Combination with a High Barrier to Resistance.
    Antimicrob Agents Chemother. 2022 May 2:e0222321. doi: 10.1128/aac.02223.
    >> Share

    April 2022
  25. ACOSTA RK, D'Antoni ML, Mulato A, Yant SR, et al
    Forgiveness of INSTI-Containing Regimens at Drug Concentrations Simulating Variable Adherence In Vitro.
    Antimicrob Agents Chemother. 2022 Apr 7:e0203821. doi: 10.1128/aac.02038.
    >> Share

    March 2022
  26. MOORE K, Thakkar N, Magee M, Sevinsky H, et al
    Pharmacokinetics of Temsavir, the Active Moiety of the HIV-1 Attachment Inhibitor Prodrug, Fostemsavir, Coadministered with Cobicistat, Etravirine, Darunavir/Cobicistat, or Darunavir/Ritonavir with or without Etravirine in Healthy Participants.
    Antimicrob Agents Chemother. 2022 Mar 22:e0225121. doi: 10.1128/aac.02251.
    >> Share

  27. WALLACE J, Gonzalez H, Rajan R, Narasipura SD, et al
    Anti-HIV Drugs Cause Mitochondrial Dysfunction in Monocyte-Derived Macrophages.
    Antimicrob Agents Chemother. 2022 Mar 16:e0194121. doi: 10.1128/aac.01941.
    >> Share

  28. MWANGI JN, Gilliland WM Jr, White N, Sykes C, et al
    Mass Spectroscopy Imaging of Hair Strands Captures Short-Term and Long-Term Changes in Emtricitabine Adherence.
    Antimicrob Agents Chemother. 2022 Mar 10:e0217621. doi: 10.1128/aac.02176.
    >> Share

    January 2022
  29. JEFFREY JL, St Clair M, Wang P, Wang C, et al
    Impact of Integrase Sequences From HIV-1 Subtypes A6/A1 on the In Vitro Potency of Cabotegravir or Rilpivirine.
    Antimicrob Agents Chemother. 2022 Jan 3:AAC0170221. doi: 10.1128/AAC.01702.
    >> Share

  30. AMANO M, Yedidi RS, Salcedo-Gomez PM, Hayashi H, et al
    Fluorine-Modifications Contribute to Potent Antiviral Activity against Highly Drug-Resistant HIV-1 and Favorable Blood-Brain Barrier (BBB) Penetration Property of Novel Central Nervous System (CNS)-targeting HIV-1 Protease Inhibitors In Vitro.
    Antimicrob Agents Chemother. 2022 Jan 3:AAC0171521. doi: 10.1128/AAC.01715.
    >> Share

    November 2021
  31. LU CM, Cheng JS, Sun WC, Chen WC, et al
    Tenofovir versus lamivudine followed by tenofovir in severe exacerbation of hepatitis B: a randomized controlled study.
    Antimicrob Agents Chemother. 2021 Nov 22:AAC0166421. doi: 10.1128/AAC.01664.
    >> Share

  32. BOYER PL, Rehm CA, Sneller MC, Mican J, et al
    A Combination of Amino Acid Mutations Leads to Resistance to Multiple Nucleoside Analogs in Reverse Transcriptases from HIV-1 Subtypes B and C.
    Antimicrob Agents Chemother. 2021 Nov 1:AAC0150021. doi: 10.1128/AAC.01500.
    >> Share

    October 2021
  33. UNDERWOOD M, Horton J, Nangle K, Hopking J, et al
    Integrase Inhibitor Resistance Mechanisms and Structural Characteristics in Antiretroviral Therapy-Experienced, Integrase Inhibitor-Naive Adults With HIV-1 Infection Treated With Dolutegravir Plus 2 Nucleoside Reverse Transcriptase Inhibitors in the D
    Antimicrob Agents Chemother. 2021 Oct 25:AAC0164321. doi: 10.1128/AAC.01643.
    >> Share

    September 2021
  34. ASANTE-APPIAH E, Lai J, Wan H, Yang D, et al
    Impact of HIV-1 Resistance-associated Mutations on Susceptibility to Doravirine: Analysis of Real-world Clinical Isolates.
    Antimicrob Agents Chemother. 2021 Sep 27:AAC0121621. doi: 10.1128/AAC.01216.
    >> Share

  35. CILENTO ME, Reeve AB, Michailidis E, Ilina TV, et al
    Development of Human Immunodeficiency Virus Type 1 Resistance to 4'-Ethynyl-2-Fluoro-2'-Deoxyadenosine (EFdA) Starting with Wild-Type or Nucleoside Reverse Transcriptase Inhibitor Resistant-Strains.
    Antimicrob Agents Chemother. 2021 Sep 13:AAC0116721. doi: 10.1128/AAC.01167.
    >> Share

  36. CHAUHAN R, Li Q, Woodson ME, Gasonoo M, et al
    Efficient Inhibition of Hepatitis B Virus Replication and cccDNA Formation by HBV Ribonuclease H Inhibitors During Infection.
    Antimicrob Agents Chemother. 2021 Sep 13:AAC0146021. doi: 10.1128/AAC.01460.
    >> Share

    July 2021
  37. ERTURK US, Mete B, Ozaras R, Saltoglu N, et al
    Plasma and Breast Milk Pharmacokinetics of Tenofovir Disoproxil Fumarate in Nursing Mother with Chronic Hepatitis B-Infant Pairs.
    Antimicrob Agents Chemother. 2021 Jul 26:AAC0111021. doi: 10.1128/AAC.01110.
    >> Share

  38. WU G, Zhou H, Wu J, Lv D, et al
    Pharmacokinetics, safety and tolerability of ravidasvir, with and without danoprevir/ritonavir, in healthy subjects.
    Antimicrob Agents Chemother. 2021 Jul 12:AAC0060021. doi: 10.1128/AAC.00600.
    >> Share

    April 2021
  39. CRANE JK, Alvarado CL, Sutton MD
    Role of the SOS Response in the Generation of Antibiotic Resistance In Vivo.
    Antimicrob Agents Chemother. 2021 Apr 19. pii: AAC.00013.
    >> Share

  40. SUNDELL J, Wijk M, Bienvenu E, Abelo A, et al
    Factors affecting the pharmacokinetics of pyrazinamide and its metabolites in patients co-infected with HIV - implications for individualized dosing.
    Antimicrob Agents Chemother. 2021 Apr 19. pii: AAC.00046.
    >> Share

    March 2021
  41. SCHOLZ EMB, Mwangi JN, De la Cruz G, Nekorchuk M, et al
    Quantitative Imaging Analysis of the Spatial Relationship between Antiretrovirals, RT-SHIV RNA, and Collagen in the Mesenteric Lymph Nodes of Nonhuman Primates.
    Antimicrob Agents Chemother. 2021 Mar 29. pii: AAC.00019.
    >> Share

  42. PENE DUMITRESCU T, Joshi SR, Xu J, Zhan J, et al
    A Phase I Evaluation of the Pharmacokinetics and Tolerability of the HIV-1 Maturation Inhibitor GSK3640254 and Tenofovir Alafenamide/Emtricitabine in Healthy Participants.
    Antimicrob Agents Chemother. 2021 Mar 22. pii: AAC.02173.
    >> Share

  43. DORGHAM K, Neumann AU, Decavele M, Luyt CE, et al
    Considering Personalized Interferon Beta Therapy for COVID-19.
    Antimicrob Agents Chemother. 2021;65.
    >> Share

  44. WHITE KL, Osman N, Cuadra-Foy E, Brenner BG, et al
    Long Dissociation of Bictegravir from HIV-1 Integrase-DNA Complexes.
    Antimicrob Agents Chemother. 2021 Mar 1. pii: AAC.02406.
    >> Share

    February 2021
  45. MARTINEZ MA
    Plitidepsin: a repurposed drug for the treatment of COVID-19.
    Antimicrob Agents Chemother. 2021 Feb 8. pii: AAC.00200.
    >> Share

  46. MANDAL S, Prathipati PK, Sunagawa SW, Destache CJ, et al
    A new combination bictegravir+tenofovir alafenamide nanoformulation with prolonged sustained-drug-release potency for HIV-1 PrEP: A concept evaluation study.
    Antimicrob Agents Chemother. 2021 Feb 1. pii: AAC.02320.
    >> Share

    December 2020
  47. ZANDI K, Amblard F, Musall K, Downs-Bowen J, et al
    Repurposing Nucleoside Analogs for Human Coronaviruses.
    Antimicrob Agents Chemother. 2020;65.
    >> Share

  48. EKE AC, Shoji K, Best BM, Momper JD, et al
    Population Pharmacokinetics of Tenofovir in Pregnant and Postpartum Women using Tenofovir Disoproxil Fumarate.
    Antimicrob Agents Chemother. 2020 Dec 14. pii: AAC.02168.
    >> Share

    October 2020
  49. CALCAGNO A, Dal Conte I, Cattaneo D, Testi R, et al
    Low Tenofovir Plasma Exposure in HIV Oral Pre-exposure Prophylaxis Recipients with Gastrointestinal Disorders.
    Antimicrob Agents Chemother. 2020 Oct 26. pii: AAC.01902.
    >> Share

  50. WANG X, Mallikaarjun S, Gibiansky E
    Population Pharmacokinetic Analysis of Delamanid in Patients with Pulmonary Multi-Drug Resistant Tuberculosis.
    Antimicrob Agents Chemother. 2020 Oct 26. pii: AAC.01202.
    >> Share

  51. ELDESOUKY HE, Salama EA, Lanman NA, Hazbun TR, et al
    Potent synergistic interactions between lopinavir and azole antifungal drugs against emerging multidrug-resistant Candida auris.
    Antimicrob Agents Chemother. 2020 Oct 12. pii: AAC.00684.
    >> Share

  52. BOWMAN ER, Cameron C, Richardson B, Kulkarni M, et al
    In vitro exposure of leukocytes to HIV pre-exposure prophylaxis (PrEP) decreases mitochondrial function and alters gene expression profiles.
    Antimicrob Agents Chemother. 2020 Oct 5. pii: AAC.01755.
    >> Share

  53. ZHOU YF, Liu P, Dai SH, Sun J, et al
    Activity of tigecycline or colistin in combination with zidovudine against Escherichia coli harboring tet(X) and mcr-1.
    Antimicrob Agents Chemother. 2020 Oct 5. pii: AAC.01172.
    >> Share

  54. HUGHES E, Imperial M, Wallender E, Kajubi R, et al
    Piperaquine exposure is altered by pregnancy, HIV and nutritional status in Ugandan women.
    Antimicrob Agents Chemother. 2020 Oct 5. pii: AAC.01013.
    >> Share

  55. BENAMOR TEIXEIRA ML, Fuller TL, Fragoso da Silveira Gouvea MI, Santos Cruz ML, et al
    Efficacy of Three Antiretroviral Regimens Initiated during Pregnancy: Clinical Experience in Rio de Janeiro.
    Antimicrob Agents Chemother. 2020 Oct 5. pii: AAC.01068.
    >> Share

    August 2020
  56. VADDADY P, Kandala B, Yee KL
    Population Pharmacokinetic and Pharmacodynamic Analysis to Evaluate a Switch to Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate in People Living with HIV-1.
    Antimicrob Agents Chemother. 2020 Aug 31. pii: AAC.00590.
    >> Share

  57. FERNANDEZ-CRUZ A, Ruiz-Antoran B, Munoz-Gomez A, Sancho-Lopez A, et al
    A Retrospective Controlled Cohort Study of the Impact of Glucocorticoid Treatment in SARS-CoV-2 Infection Mortality.
    Antimicrob Agents Chemother. 2020;64.
    >> Share

  58. FINTELMAN-RODRIGUES N, Sacramento CQ, Ribeiro Lima C, Souza da Silva F, et al
    Atazanavir, alone or in combination with ritonavir, inhibits SARS-CoV-2 replication and pro-inflammatory cytokine production.
    Antimicrob Agents Chemother. 2020 Aug 5. pii: AAC.00825.
    >> Share

  59. ARQUEZ MA, Martin-Alonso S, Gorelick RJ, Scott WA, et al
    Nucleocapsid protein precursors NCp9 and NCp15 suppress ATP-mediated rescue of AZT-terminated primers by HIV-1 reverse transcriptase.
    Antimicrob Agents Chemother. 2020 Aug 3. pii: AAC.00958.
    >> Share

    July 2020
  60. DANION F, Ruch Y, Fourtage M, Kaeuffer C, et al
    The Good, the Bad, and the Hoax: When Publication Instantaneously Impacts Treatment Strategies for COVID-19.
    Antimicrob Agents Chemother. 2020;64.
    >> Share

  61. DAVOUDI-MONFARED E, Rahmani H, Khalili H, Hajiabdolbaghi M, et al
    Efficacy and safety of interferon beta-1a in treatment of severe COVID-19: A randomized clinical trial.
    Antimicrob Agents Chemother. 2020 Jul 13. pii: AAC.01061.
    >> Share

  62. ZHENG Y, Hirt D, Delma S, Lui G, et al
    Effect of pregnancy on unbound raltegravir concentrations in the ANRS 160 Ralfe trial.
    Antimicrob Agents Chemother. 2020 Jul 13. pii: AAC.00759.
    >> Share

  63. MARZOLINI C, Stader F, Stoeckle M, Franzeck F, et al
    Effect of Systemic Inflammatory Response to SARS-CoV-2 on Lopinavir and Hydroxychloroquine Plasma Concentrations.
    Antimicrob Agents Chemother. 2020 Jul 8. pii: AAC.01177.
    >> Share

  64. MARTINEZ MA
    Clinical trials of repurposed antivirals for SARS-CoV-2.
    Antimicrob Agents Chemother. 2020 Jul 6. pii: AAC.01101.
    >> Share

  65. DUMOND JB, Bay CP, Nelson JAE, Davalos A, et al
    Intracellular Tenofovir and Emtricitabine Concentrations in Younger and Older Women with HIV Receiving Tenofovir Disoproxil Fumarate/Emtricitabine.
    Antimicrob Agents Chemother. 2020 Jul 6. pii: AAC.00177.
    >> Share

    June 2020
  66. GEORGI F, Andriasyan V, Witte R, Murer L, et al
    The FDA-approved drug Nelfinavir inhibits lytic cell-free, but not cell-associated non-lytic transmission of human adenovirus.
    Antimicrob Agents Chemother. 2020 Jun 29. pii: AAC.01002.
    >> Share

  67. SMITH SJ, Zhao XZ, Passos DO, Lyumkis D, et al
    HIV-1 Integrase Inhibitors that are active against Drug-Resistant Integrase Mutants.
    Antimicrob Agents Chemother. 2020 Jun 29. pii: AAC.00611.
    >> Share

  68. PARSONS TL, Gwenden KN, Marzinke MA
    Inter-species Differences in Tenofovir Alafenamide Fumarate Stability in Plasma.
    Antimicrob Agents Chemother. 2020 Jun 15. pii: AAC.00930.
    >> Share

  69. SQUIRES KE, Mayers DL, Bluemling GR, Kolykhalov AA, et al
    ATI-2173, A Novel Liver-Targeted Non-Chain Terminating Nucleotide for HBV Cure Regimens.
    Antimicrob Agents Chemother. 2020 Jun 15. pii: AAC.00836.
    >> Share

    May 2020
  70. RAJOLI RKR, Demkovich ZR, Flexner C, Owen A, et al
    Predicting pharmacokinetics of a tenofovir alafenamide subcutaneous implant using PBPK modelling.
    Antimicrob Agents Chemother. 2020 May 18. pii: AAC.00155.
    >> Share

    March 2020
  71. MARTINEZ MA
    Compounds with therapeutic potential against novel respiratory 2019 coronavirus.
    Antimicrob Agents Chemother. 2020 Mar 9. pii: AAC.00399.
    >> Share

  72. WU G, Tang W, Lv D, Wu L, et al
    Effects of Tenofovir on Single-dose Pharmacokinetics of Intravenous Morinidazole in Healthy Chinese Subjects.
    Antimicrob Agents Chemother. 2020 Mar 9. pii: AAC.02067.
    >> Share

    February 2020
  73. MCCORMICK KD, Penrose KJ, Brumme CJ, Harrigan R, et al
    Discordance between Etravirine Phenotype and Genotype-based Predicted Phenotype for Subtype C HIV-1 from First-line Antiretroviral Therapy Failures in South Africa.
    Antimicrob Agents Chemother. 2020 Feb 18. pii: AAC.02101.
    >> Share

  74. RABIE H, Tikiso T, Lee J, Fairlie L, et al
    Abacavir exposure in children co-treated for tuberculosis with rifampicin and super-boosted lopinavir-ritonavir.
    Antimicrob Agents Chemother. 2020 Feb 18. pii: AAC.01923.
    >> Share

  75. FRANCIS J, Barnes KI, Workman L, Kredo T, et al
    Drug-drug Interactions between Lumefantrine and Commonly-used Antiretroviral Treatment: An Individual Participant Data Population Pharmacokinetic Meta-Analysis.
    Antimicrob Agents Chemother. 2020 Feb 18. pii: AAC.02394.
    >> Share

  76. ISRAEL S, Elinav H, Elazary R, Porat D, et al
    INCREASED EXPOSURE TO ANTIRETROVIRALS FOLLOWING SLEEVE GASTRECTOMY - A CASE REPORT.
    Antimicrob Agents Chemother. 2020 Feb 3. pii: AAC.02453.
    >> Share

  77. EKE AC, Wang J, Amin K, Shapiro DE, et al
    Fosamprenavir with Ritonavir Pharmacokinetics During Pregnancy.
    Antimicrob Agents Chemother. 2020 Feb 3. pii: AAC.02260.
    >> Share

    January 2020
  78. MARGOT N, Ram R, Abram M, Haubrich R, et al
    Antiviral Activity of Tenofovir Alafenamide against HIV-1 with Thymidine Analog Mutations and M184V.
    Antimicrob Agents Chemother. 2020 Jan 27. pii: AAC.02557.
    >> Share

    December 2019
  79. ABDULLAHI ST, Soyinka JO, Olagunju A, Bolarinwa RA, et al
    Differential impact of nevirapine on artemether-lumefantrine pharmacokinetics in individuals stratified by CYP2B6 c.516G>T genotypes.
    Antimicrob Agents Chemother. 2019 Dec 23. pii: AAC.00947.
    >> Share

  80. SU JT, Simpson SM, Sung S, Bryndza Tfaily E, et al
    A Subcutaneous Implant of Tenofovir Alafenamide Fumarate Causes Local Inflammation and Tissue Necrosis in Rabbits and Macaques.
    Antimicrob Agents Chemother. 2019 Dec 23. pii: AAC.01893.
    >> Share

    November 2019
  81. SRINIVAS N, Cottrell M, Maffuid K, Prince HA, et al
    A Translational Approach to Predicting the Efficacy of Maraviroc-based Regimens as HIV Pre-exposure Prophylaxis.
    Antimicrob Agents Chemother. 2019 Nov 18. pii: AAC.01729.
    >> Share

    October 2019
  82. DLAMINI S, Kuipa M, Enfield K, Skosana S, et al
    Reciprocal modulation of antiretroviral drug and steroid receptor function in vitro.
    Antimicrob Agents Chemother. 2019 Oct 28. pii: AAC.01890.
    >> Share

  83. ZHAO N, Jia B, Zhao H, Xu J, et al
    A first-in-human trial of GLS4, a novel inhibitor of hepatitis B virus capsid assembly, following single- and multiple-ascending oral dose studies with or without ritonavir in healthy adult volunteers.
    Antimicrob Agents Chemother. 2019 Oct 21. pii: AAC.01686.
    >> Share

  84. SALADINI F, Giannini A, Boccuto A, Dragoni F, et al
    Comparable in vitro activity of second-generation HIV-1 integrase strand transfer inhibitors (INSTIs) on HIV-1 clinical isolates with INSTI resistance mutations.
    Antimicrob Agents Chemother. 2019 Oct 14. pii: AAC.01717.
    >> Share

  85. DEVANATHAN AS, Pirone JR, Akkina R, Remling-Mulder L, et al
    Antiretroviral penetration across three preclinical animal models and humans in eight putative HIV viral reservoirs.
    Antimicrob Agents Chemother. 2019 Oct 14. pii: AAC.01639.
    >> Share

    January 2019
  86. YOSHINAGA T, Miki S, Kawauchi-Miki S, Seki T, et al
    Barrier to resistance of dolutegravir in two-drug combinations.
    Antimicrob Agents Chemother. 2019 Jan 2. pii: AAC.02104.
    >> Share

    October 2018
  87. HU Y, Liu Y, Coates A
    Azidothymidine produces synergistic activity in combination with colistin against antibiotic-resistant Enterobacteriaceae.
    Antimicrob Agents Chemother. 2018 Oct 29. pii: AAC.01630.
    >> Share

    August 2018
  88. SPIVAK AM, Nell RA, Petersen M, Martins L, et al
    Synthetic Ingenols Maximize Protein Kinase C-Induced HIV-1 Latency Reversal.
    Antimicrob Agents Chemother. 2018 Aug 13. pii: AAC.01361.
    >> Share


Free Medical Abstracts
Privacy Policy
Sponsors
Share

© Amedeo 1997-2016